Medical network - on April 11, according to the data provided by the ernst & young, the pharmaceutical industry's turnover of more than $200 billion last year, basic flat with the previous two years. However, HBM Partners, the company's data show that last year the global biopharmaceutical industry deal volume fell 35% year on year, from 2015, the company estimates of $228.1 billion to $2016 in 148.2 billion. Zephyr biotechnology report listed trading gross decline is more apparent, according to the statistics, the pharmaceutical industry trade totaled $2016 in 94.62 billion, less than $2015 in 121.294 billion. Deloitte research shows that the pharmaceutical industry in 2016 gross trading down from $118 billion in 2015 to $91 billion. Although various agencies of statistical caliber is not consistent, but can be seen from a general trend, namely 2016 curbed mergers and acquisitions activity in the pharmaceutical industry.
President promised to reduce trump public expenditures in medication, the expected by publishing marketization mechanism and more friendly to industry policy to achieve this goal. , for instance, allow Medicaid (Medicaid) and a health insurance program (Medicare) and drug developers, price negotiations, the United States enterprise backflow offshore funds rate from 35% to 10%. Ernst & young has pointed out, such a policy could encourage mergers and acquisitions activity in the field of medicine this year is much higher than last year's level.
The m&a market is expected to be more popular for quite a few enterprises may be acquired by the close attention and discussion, a few days ago, GEN website "prey" list released ten m&a. Compared with last year, this year's list of the six new faces. On the list of each company, GEN explains the takeover rumors come from where, and why it will become a takeover target.
Like in the past few years, small and medium-sized market value of biopharmaceutical company is still the life of the merger and acquisition activity, because of its in new drug approvals, new indications of clinical research project success to expand sales, is expected to add billions of dollars in sales) showed good prospects.
1, the best health
After the "lean" more attractive
Since found itself to takeover rumors, best health (Biogen) has adopted a series of actions (most have been welcomed by investors). In August of last year, the Wall Street journal reported that the national health as a potential acquisition targets, caused the MSD (Merck) and Allergan (Allergan) of interest.
Then, the best athletes hemophilia and other rare blood disease became a new company called Bioverativ business stripping. Market analysts pointed out that this action may make the health become more attractive takeover target. By the Evercore ISI company to market analysts, in a survey conducted by the best health became the most likely to be acquired one of the top three biological pharmaceutical companies.
Stripping Bioverativ makes the best health to focus on treatment of eye disease and neural system disease, such as for spinal muscle atrophy of the first treatment is developed by the national health Spinraza (nusinersen), the drug approved by the FDA listed in December.
Best health become targets of another reason is that the drug to the management of multiple sclerosis (MS) in a leading position in the market, the main product Tecfidera generated sales of $3.968 billion last year, up 9% from 2015. The other MS drugs Plegridy (polyethylene glycol interferon beta 1 a) sales rose 42% year-on-year in 2016, to $482 million. Achieve $2016 in sales, in 2016 (up 10%), on the basis of the health of the net income of $3.703 billion, up 4% from a year earlier.
2, BioMarin
Product line force strong growth
If there is no BioMarin, biological pharmaceutical target list will be. GEN published the list for the first time since 2013, BioMarin this rare disease drug developers be included every time. In 2013, the market rumors, said Roche (Roche) its acquisition looked BioMarin.
This year, the stock columnist Michael cloth rush (Michael Brush) according to RBC capital markets analyst Michael (Michael Yee) comments, in MarketWatch online financial BioMarin listed as "one of the five big takeover candidate targets". In the Evercore ISI in a survey conducted by the company, BioMarin has become most likely to be acquired one of the top three biological pharmaceutical companies.
Both market analysts mentioned BioMarin sale of drugs, and is developing the drug candidates. BioMarin sales revenue reached $1.117 billion last year, up 26% from a year earlier. Two of them have been listed in the drug at A breathtaking pace of growth: Morquio syndrome A enzyme replacement therapy Vimizim products net income of $354 million in 2016, up 55%; And get the first and only fda-approved phenyl acetone urine disease (PKU) drugs Kuvan for sales of $348 million, up 46% from a year earlier.
In the research and development level, BioMarin used to treat Batten's disease (Batten diseases) candidate drugs Brineura is subject to the approval by the FDA, the FDA is expected to make a decision on April 27. The drug at the same time accept the European regulators for approval. In addition, in the second quarter of this year, the company is expected to pegvaliase used in the treatment of phenyl acetone urine biologics license application submitted. At the end of 2016, BioMarin vosoritide selected drugs used for the gnome symptom of 5 ~ 14 years old children begin Ⅲ period test, Ⅱ period test has achieved positive results.
3, BMS
Size exceeds one hundred billion
Bristol-myers squibb (BMS), the pharmaceutical giant into at least two active investors in the line of sight, causing the market to its likely takeover speculation. Is one of the investor Carl Icahn (Carl c. Icahn), in February this year, the Wall Street journal said Icahn had bought shares in the BMS, to this, he neither confirm nor deny. A week later, he hired gm technology pioneer Richard Mulligan (Richard c. Mulligan) as a portfolio manager, suggests that he as a biological pharmaceutical active investors, to play a bigger role.
In addition, the end of last year, Jana company become a shareholder in the BMS, as of December 31, the company has 3.9 million shares of BMS shares, worth $226 million, however, that stake is still far lower than 1%. , Reuters reported that this year there will be a substantial increase, but will still be less than 1%. However, Jana investment has paid off, in February, the BMS nominate three new independent directors into its board of directors.
On February 23, Motley Fool financial services analyst Todd Campbell (Todd Campbell) is a list of five potential takeover of BMS company: Amgen (Amgen), Gilead Sciences (Gilead Sciences), Pfizer (Pfizer), roche and sanofi-aventis (Sanofi).
StreetInsider website will gilead, Pfizer, roche and Novartis (Novartis) as a potential acquirer. StreetInsider said that if the implementation of trade, then the deal could be worth up to $120 billion.
4, Exelixis
Have potential "blockbuster"
In the biological pharmaceutical industry, enterprises to change the fate of the fast. In 2015, Exelixis also is on Wall Street, losers just a year later, the company is on the right track, into GEN 2016 top ten enterprise stock gains. This shift also makes the company is a separate lists - attractive acquisition targets.
Exelixis last year in the development of drug Cabometyx has made a series of positive results, the drug in Ⅲ period test results can renal cell carcinoma (RCC) with novartis everolimus treatment drugs. Last April, listed Cabometyx won FDA approval, in September, it allowed for sale in European market.
Market analysts believe that gilead sciences is expected to become the potential acquirer Exelixis, although acquisition Exelixis is expensive, but it will boost geely's influence in the field of anti-tumor, also can let it has a potential "blockbuster" class antitumor drugs.
5, Genfit
NASH field "beacon"
Nonalcoholic fatty hepatitis (NASH) has become one of the most popular areas of biopharmaceutical industry, this situation will undoubtedly make focus on drugs for NASH Genfit outside wagging of mergers and acquisitions "prey". In early march, this speculation is rife that because before this, StreetInsider said, citing unnamed sources, novartis will almost a takeover Genfit agreement.
The company takeover rumors began in December last year, the earliest when Genfit reportedly are exploring the possibility of selling the company. Bloomberg said, citing unnamed sources, including sanofi-aventis, novartis and hill (Shire), pharmaceutical companies may be interested in Genfit.
If the Genfit is on the shelf, suitors perhaps will face fierce competition. Last year, allergan, claim to be the leader in the field of NASH, at that time, it announced plans to $1.695 billion deal to buy Tobira Therapeutics, as well as to Akarna Therapeutics to pay $50 million upfront costs. In January of this year, geely's CEO John Milligan (John Milligan), said NASH drug development will become one of the priorities for the company in 2017. In addition, Pfizer has two drugs are in NASH Ⅰ period development phase.
6, Incyte
Growth bright eye Research and development of a strong
As the Jakafi continued sales growth momentum, and talking about the possibility of Incyte become a takeover target. Bone marrow fibrosis and polycythemia vera (PV) indications to help push the sales of Jakafi strong growth, the drug product net income of $853 million in 2016, up 42% from a year earlier.
In addition, the research and development of Incyte line is also very strong. In January of this year, the company Merck announced that will expand to Incyte epacadostat and MSD Keytruda combination of clinical trial plan. For the combination of drugs used in four kinds of tumor Ⅲ phase of the trial is expected to start this year. The other is in the development of drug candidates with Lilly baricitinib (Eli Lilly) cooperation, it is waiting for the FDA review, used to treat moderate to severe rheumatoid arthritis. It is already approved by the European regulators.
RBC capital markets, the company general manager/advanced biotechnology, an analyst at west MiaoNi diss (Simos Simeonidis), according to the sales revenue is growing and developing lines of strong makes Incyte a reliable target. He will Incyte included in the list of five candidates target.
7, Juno Therapeutics
Tumbling shares tumbled
A year ago, in the CAR - T on the development of tumor immunotherapy drugs, Juno Therapeutics have with Kite Pharma and novartis is neck and neck. Later, the company in its main CAR - T drug candidates JCAR015 Ⅱ stage ROCKET tests of five participate type B cells of acute lymphocytic leukemia (ALL) patients died of brain edema. Today, Juno Therapeutics have been left behind, will be the first tumor immunotherapy drugs to the market, also need at least a year's time.
This year on March 1, Juno Therapeutics for JCAR015 development was ended. Company will focus on below a rapid development process of CAR - T JCAR017 candidate drugs, in December, in patients with invasive non-hodgkin's lymphoma (NHL) in the test, it comes to some promising preliminary research data.
Since last July, Juno was the first to admit that there are three subjects death, since the company's share price has fallen by 45%, from $40.82 on July 7 last year fell to $22.48 this year on March 10. Market observers said that Juno's share price is expected to rebound this year, because there has been speculation the company could be acquired.
8, The Medicines Company
PCSK9 inhibitors to gain advantage
Sometimes, a biopharmaceutical Company acquisition rumors, because it can benefit from competitors in related research, The Medicines Company as was The case with The (TMC). From December 26 to February 28, the company's shares rose 26%, from $119 to $150.25.
During this period, amgen from its FOURIER clinical trials have a positive study data, research has shown that PCSK9 inhibitors Repatha greatly reduce the risk of cardiovascular events.
Analytic personage points out, is also good for TMC amgen's the good news, because it is for companies to develop a cholesterol-lowering drugs inclisiran (formerly known as PCSK9si or ALN - PCSsc) is also aimed at PCSK9 targets. On November 15 last year, TMC and it announced that it from Ⅱ ORION - 1 got positive results in the study.
Famous Wall Street investment bank Jefferies has ranked TMC five this year may be one of the goals of the acquisition, "medical tech communication" Jay Silverman (Jay Silverman) also last fall to the company as a takeover target.
9, Neurocrine Biosciences
One of the best small business
On February 14, in a statement, the company CEO Kevin Gorman (Kevin Gorman said that 2017 will be Neurocrine key for one year. The development of drugs for the treatment of tardive dyskinesia Ingrezza is subject to the approval by the FDA, the FDA is expected to make a decision on April 11.
In January of this year, Neurocrine together with several other companies are classified as a model of small biotechnology companies. BMO capital markets analyst Ian suo get (m. Ian Somaiya) said that if, as expected, trump's enterprises overseas money back tax proposal is passed, then Neurocrine may also become a large biopharmaceutical company targets.
10, Tesaro
Listed third PARP inhibitors
In June last year, a Ⅲ phase trial of the positive results not only make Tesaro's share price has doubled, but also make it become a sought-after targets in investors. Since then, discussion of Tesaro acquisition possibilities intensified.
In phase Ⅲ NOVA trials, the drug called Niraparib reached the primary end point of progression-free surial in patients with ovarian cancer. Last November, be submitted to the FDA Tesaro Niraparib of new drug applications (NDA). A month later, the drug obtained FDA priority review qualification, and listed on the recently passed the approval.
Niraparib will be with the other two in the market compete PARP inhibitors of ovarian cancer, one of the only Lynparza AstraZeneca (AstraZeneca), another one is Clovis Rubraca Oncology company, which in December 19, approved by the FDA.
In October last year, ubs analyst Alicia Yang (she Young), and colleagues told investors that Tesaro has long been the media as a potential acquisition targets, the reason is that the market demand for assets in the later study stage of oncology has been high, particularly in the field of PARP inhibitors. |
